Skip to main content

Advertisement

Table 3 Multivariate overall survival analyses including sidedness, the TP53 mutation status, and their interaction as covariates

From: Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie)

  Coeff eCoeff (HR) 95%-CI p adjusted p
Stratified according to therapy (n = 141, number of events = 118)
 Sidedness 0.57 1.77 1.06–2.95 0.030 0.090
 TP53 mutation status 0.38 1.47 0.93–2.30 0.097 0.145
 Sidedness: TP53 mutation status interaction 0.04 1.04 0.40–2.74 0.930 0.930
Anti-VEGF therapy (n = 72, number of events = 60)
 Sidedness 0.34 1.40 0.71–2.76 0.326 0.489
 TP53 mutation status 0.21 1.23 0.67–2.26 0.507 0.507
 Sidedness: TP53 mutation status interaction −1.20 0.30 0.04–2.52 0.268 0.489
Anti-EGFR therapy (n = 29, number of events = 26)
 Sidedness 1.29 3.64 1.27–10.4 0.016 0.049
 TP53 mutation status 1.00 2.71 1.02–7.17 0.045 0.068
 Sidedness: TP53 mutation status interaction −0.39 0.67 0.10–4.55 0.686 0.686
  1. Multivariate survival analysis using Cox’s regression model - stratified according to therapy, for the group of anti-VEGF treated patients, and for the group of anti-EGFR treated patients